Overview

TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).

Status:
Completed

Trial end date:
2012-10-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to demonstrate that the antibacterial activity of TMC207 is better than placebo when added to a standardized Background Regimen (BR) for treatment of multi-drug resistant TB. Also safety and tolerability will be evaluated.

Phase:

Phase 2

Details

Lead Sponsor:

Janssen Infectious Diseases BVBA

Treatments:

Anti-Bacterial Agents
Bedaquiline
Diarylquinolines